Paul Tudor Jones Eli Lilly & CO Put Options Transaction History

Tudor Investment Corp Et Al

7 transactions

Quarter	Operation	Price Per put	puts change	puts Held
Q2 2024 Aug 14, 2024	SELL	$724.87 - $909.04 $13.2 Million - $16.5 Million	-18,200 Reduced 52.3%	16,600 $15 Million
Q1 2024 May 15, 2024	BUY	$592.2 - $792.28 $13.7 Million - $18.3 Million	23,100 Added 197.44%	34,800 $27.1 Million
Q4 2023 Feb 14, 2024	SELL	$525.19 - $619.13 $5.04 Million - $5.94 Million	-9,600 Reduced 45.07%	11,700 $6.82 Million
Q3 2023 Nov 15, 2023	BUY	$434.7 - $599.3 $8.56 Million - $11.8 Million	19,700 Added 1231.25%	21,300 $11.4 Million
Q2 2023 Aug 14, 2023	SELL	$350.74 - $468.98 $350,740 - $468,980	-1,000 Reduced 38.46%	1,600 $750,000
Q1 2023 May 15, 2023	BUY	$310.63 - $364.82 $807,638 - $948,532	2,600 New	2,600 $893,000
Q3 2022 Nov 14, 2022	BUY	$296.48 - $337.87 $266,832 - $304,083	900 New	900 $291,000

3,872

751M

6.34M

7.97M

Ticker LLY
Exchange NYSE
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 950,174,976
Market Cap $834B
Description
Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. It offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; and Jardiance, T...

Get notified when there are updates to the investment portfolio of Tudor Investment Corp Et Al, based on Form 13F filings with the SEC.

Stay updated on Tudor Investment Corp Et Al and Paul Tudor Jones with notifications on news.